KEY TAKEWAYS The Alzheimer’s drug pipeline is rapidly evolving and gaining momentum with a growing, diverse set of 138+ drugs targeting multiple pathways. Key trends include real-world validation of anti-amyloid … Read More

KEY TAKEWAYS Blood biomarker tests have reached levels of accuracy on par with more intrusive diagnostic tests for Alzheimer’s disease such as cerebrospinal fluid analysis (CSF) and PET imaging. Blood … Read More

KEY TAKEWAYS Pre-clinical Alzheimer’s disease (PCAD) is a condition in which Alzheimer’s disease in the form of abnormal amyloid protein concentrations form in the brain before symptoms of Alzheimer’s disease … Read More